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Efﬁcacy and safety of platinum-chromium everolimus-eluting stents
compared with other second-generation drug-eluting stents.
Meta-analysis from 5 randomized trials including 7,896 patients
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BACKGROUND Platinum-chromium alloy has been recently incorpo-
rated to the drug-eluting stent platforms, mainly everolimus-eluting
stents (Promus Element -PE- stent). The objective of the study was to
evaluate the efﬁcacy and safety of PE in comparison with other sec-
ond-generation drug-eluting stents.
METHODS A meta-analysis from 5 published randomized trials that
compared PE with other second-generation drug-eluting stents was
performed. Overall, 7,896 patients were included: 3,330 allocated to
PE, and 4,566 to other stents (3,415 to cobalt-chromium everolimus-
eluting, 906 to zotarolimus-eluting, and 245 to biolimus-eluting
stent). In all trials, planned follow-up was 12 months.
RESULTS Clinical events at 12 months were infrequent (target lesion
revascularization < 2%), and numerically lower in patients allocated
to PE, but differences were not statistically different (see table). The
rate of deﬁnitive/probable stent thrombosis after PE implantation at 1
year was < 0.5%.PE stent Control p value OR (95% CI)Target vessel failure (%) 4.6 5.3 0.65 0.95 (0.77, 1.18)Death (%) 2.5 2.7 0.96 0.99 (0.74, 1.33)Cardiac death (%) 1.2 1.3 0.59 0.89 (0.59 1.35)Infarction (%) 2.1 2.7 0.51 0.90 (0.67, 1.22)Target vessel
revascularization (%)2.2 2.6 0.70 0.74 (0.70, 1.27)Target lesion
revascularization (%)1.6 1.8 0.88 0.97 (0.69, 1.38)Stent thrombosis (%) 0.46 0.63 0.37 0.76 (0.42, 1.39)CONCLUSIONS Clinical outcomes of patients treated with the plat-
inum-chromium everolimus-eluting stent Promus Element is excel-
lent, with rates of target lesion revascularization and stent thrombosis
at 1 year of 1.8% and 0.46%, respectively.
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Long Term Outcomes After Primary Percutaneous Coronary Intervention:
Evidence from a Network Meta-Analysis of Trials in ST-Segment Myocardial
Infarction
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BACKGROUND The relative safety of drug-eluting stents (DES) and bare-
metal stents (BMS) in primary percutaneous coronary intervention (PPCI)
continues to be debated. We compared the long-term clinical outcomes
between 2nd generation DES and BMS for primary percutaneous coronary
intervention (PCI) using network meta-analysis.
METHODS Randomized controlled trials comparing stent types (1st
generation DES, 2nd generation DES or BMS) were considered for
inclusion. A search strategy used Medline, Embase, Cochrane da-
tabases and proceedings of the international meetings. Information
about study design, inclusion criteria and sample characteristics
were extracted. Network meta-analysis was used to pool direct
(comparison of 2nd generation DES to BMS) and indirect evidence
(1st generation DES with BMS and 2nd generation DES) from the
randomized trials.
RESULTS 12 trials comparing all stents types including 9673 pa-
tients randomly assigned to treatment groups were analyzed. Sec-
ond generation DES was associated with signiﬁcantly lower
incidence of deﬁnite or probable ST (OR 0.59, CI 0.39-0.89), MI (OR
0.59, 95% CI 0.39-0.89) and TVR at 3 years (OR 0.50: CI 0.31-0.81)
compared to BMS. In addition, there was a signiﬁcantly lower
incidence of MACE with 2nd generation DES vs. BMS (OR 0.54, CI
0.34-0.74) at 3 years. These were driven by a higher rate of TVR, MI
and stent thrombosis in the BMS group at 3 years. There was a non-
signiﬁcant reduction in the overall and cardiac mortality [OR 0.83,
CI (0.60-1.14), OR 0.88, CI (0.6-1.28)] with the use of 2nd generation
DES vs. BMS at 3 years.
CONCLUSIONS Network meta-analysis of randomized trials of pri-
mary PCI demonstrated lower incidence of MACE, MI, TVR and stent
thrombosis with 2nd generation DES compared to BMS. Use of second
generation DES for PCI in STEMI was not associated with adverse
events compared to BMS.
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Titratable drug delivery from drug ﬁlled stents
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BACKGROUND Polymer-free controlled drug elution has proved
challenging for surface-modiﬁed drug eluting stents. Drug-ﬁlled
